Insider Selling: Abbott Laboratories (ABT) EVP Sells 13,313 Shares of Stock

Abbott Laboratories (NYSE:ABT) EVP Stephen R. Fussell sold 13,313 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total transaction of $836,588.92. Following the transaction, the executive vice president now directly owns 152,343 shares in the company, valued at approximately $9,573,234.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Abbott Laboratories (NYSE ABT) traded up $0.02 during trading hours on Thursday, hitting $62.18. 7,595,767 shares of the stock traded hands, compared to its average volume of 7,436,371. Abbott Laboratories has a 12-month low of $41.85 and a 12-month high of $64.60. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The stock has a market cap of $108,720.00, a PE ratio of 310.90, a price-to-earnings-growth ratio of 1.92 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.80%. The firm had revenue of $7.59 billion during the quarter, compared to analysts’ expectations of $7.38 billion. During the same period last year, the company posted $0.65 EPS. The company’s quarterly revenue was up 42.3% compared to the same quarter last year. equities research analysts expect that Abbott Laboratories will post 2.86 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 1.80%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date is Thursday, January 11th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 560.00%.

Several large investors have recently bought and sold shares of ABT. Engineers Gate Manager LP lifted its position in Abbott Laboratories by 48.8% during the 4th quarter. Engineers Gate Manager LP now owns 37,026 shares of the healthcare product maker’s stock valued at $2,113,000 after acquiring an additional 12,140 shares during the period. Quantitative Systematic Strategies LLC lifted its position in Abbott Laboratories by 44.7% during the 4th quarter. Quantitative Systematic Strategies LLC now owns 43,540 shares of the healthcare product maker’s stock valued at $2,485,000 after acquiring an additional 13,449 shares during the period. Iberiabank Corp lifted its position in Abbott Laboratories by 129.0% during the 4th quarter. Iberiabank Corp now owns 28,105 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 15,832 shares during the period. Dean Capital Investments Management LLC purchased a new position in Abbott Laboratories during the 4th quarter valued at about $630,000. Finally, Reik & CO. LLC lifted its position in Abbott Laboratories by 17.3% during the 4th quarter. Reik & CO. LLC now owns 6,115 shares of the healthcare product maker’s stock valued at $349,000 after acquiring an additional 900 shares during the period. 71.33% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently commented on ABT shares. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays reaffirmed a “buy” rating and set a $66.00 target price on shares of Abbott Laboratories in a report on Monday, January 8th. BTIG Research lowered shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd. They noted that the move was a valuation call. Stifel Nicolaus increased their target price on shares of Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, October 19th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $65.47.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Abbott Laboratories (ABT) EVP Sells 13,313 Shares of Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/01/insider-selling-abbott-laboratories-abt-evp-sells-13313-shares-of-stock.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply